MCL1阻害剤は、がん治療薬における有望でありながら挑戦的なフロンティアであり、医薬品開発の新たな機会として大きな可能性を秘めています。MCL1阻害剤は承認されておらず、開発の最高段階が第2相臨床試験であるにもかかわらず、MCL1阻害剤は製薬会社や研究者から大きな関心を集め続けています。この関心は、がん細胞の生存においてMCL1が果たす重要な役割と、既存の治療法に対する耐性を克服するための標的としての可能性によって推進されています。
目次
Table of Content
1. Research Methodology
2. Introduction To MCL1 Inhibitors
2.1 MCL1 As A Therapeutic Target
2.2 Role of MCL1 in Cancer
3. MCL1 Inhibitors - Mechanism of Action
3.1 Indirect Inhibition of MCL1
3.2 Direct Inhibition of MCL1
4. Role of MCL1 and Clinical Innovation by Indication
4.1 Hematological Malignancies
4.1.1 Leukemia
4.1.2 Lymphoma
4.1.3 Multiple Myeloma
4.2 Solid Cancers
4.2.1 Breast cancer
4.2.2 Lung Cancer
4.2.3 Melanoma
4.2.4 Colorectal cancer
4.3 Viral Infections
5. Global MCL1 Inhibitor Drug Market Opportunity Outlook
5.1 Current Clinical Research Landscape
5.2 Future Commercialization Opportunities
6. Global MCL1 Inhibitor Drugs Clinical Trials Overview
6.1 By Company
6.2 By Country
6.3 By Indication
6.4 By Patient Segment
6.5 By Phase
7. MCL1 Inhibitors Clinical Trials Insight By Company, Country, Indication and Phase
7.1 Preclinical
7.2 Phase I
7.3 Phase I/II
7.4 Phase II
8. Competitive Landscape
8.1 Abbvie
8.2 Amgen
8.3 Anji Pharma
8.4 Ascentage Pharma
8.5 Broad Institute
8.6 Cyclacel Pharmaceuticals
8.7 Gilead Sciences
8.8 Novartis
8.9 Servier
8.10 Sirnaomics
List of Figures
Figure 4-1: MIK665 Phase I Study (NCT04702425) - Initiation and Completion Year
Figure 4-2: AZD5991 Phase I/II Study (NCT03013998) - Initiation and Completion Year
Figure 4-3: GFH009 Phase I/II Study (NCT04588922) - Initiation and Completion Year
Figure 6-1: Global - MCL1 Inhibitor Drugs Trials By Company (Numbers), 2024
Figure 6-2: Global - MCL1 Inhibitor Drugs Trials By Country (Numbers), 2024
Figure 6-3: Global - MCL1 Inhibitor Drugs Trials By Indication (Numbers), 2024
Figure 6-4: Global - MCL1 Inhibitor Drugs Trials by Patient Segment (Numbers), 2024
Figure 6-5: Global - MCL1 Inhibitor Drugs Trials By Phase (Numbers), 2024
